Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Analysts at SunTrust Banks cut their FY2017 earnings estimates for shares of Conatus Pharmaceuticals in a research report issued on Tuesday. SunTrust Banks analyst J. Boris now expects that the biotechnology company will earn ($0.60) per share for the year, down from their previous estimate of ($0.47). SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q4 2017 earnings at ($0.14) EPS, FY2018 earnings at $1.73 EPS, FY2019 earnings at $3.91 EPS, FY2020 earnings at $3.67 EPS and FY2021 earnings at $2.45 EPS.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus restated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. HC Wainwright restated a “buy” rating and issued a $17.00 price objective (down previously from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Seaport Global Securities reaffirmed a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Finally, Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $16.00.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/10/fy2017-eps-estimates-for-conatus-pharmaceuticals-inc-cnat-cut-by-analyst.html.

Conatus Pharmaceuticals (NASDAQ CNAT) opened at $4.12 on Thursday. The company has a quick ratio of 2.77, a current ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 1 year low of $1.73 and a 1 year high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million during the quarter, compared to the consensus estimate of $16.06 million. During the same quarter last year, the firm earned ($0.31) EPS.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its holdings in Conatus Pharmaceuticals by 3,098.0% during the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 18,588 shares during the period. Macquarie Group Ltd. acquired a new stake in Conatus Pharmaceuticals during the 3rd quarter worth $330,000. Bank of New York Mellon Corp grew its holdings in Conatus Pharmaceuticals by 41.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 184,021 shares of the biotechnology company’s stock worth $1,010,000 after acquiring an additional 53,678 shares during the period. New York State Common Retirement Fund grew its holdings in Conatus Pharmaceuticals by 156.4% during the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 14,700 shares during the period. Finally, California State Teachers Retirement System acquired a new stake in Conatus Pharmaceuticals during the 2nd quarter worth $261,000. 33.04% of the stock is owned by hedge funds and other institutional investors.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.